BPC-157 for Health & Longevity - Quick Reference Sheet

BPC-157 for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

BPC-157 is a laboratory-made chain of 15 amino acids, sold for tendon and joint injuries and healthy aging. It rests almost entirely on animal and cell research, plus a few clinic-run human reports without control groups. No benefit reaches even moderate confidence, and none has been tested for longevity. Reported risks are mostly theoretical or unmeasured, including uncertain product contents. Drug regulators treat it as unapproved. (Full Review)

Protocol

Common subcutaneous regimen
300–500 mcg subcutaneously
Two or three times weekly for about 8 weeks, then 8–10 weeks off; reflects reported practice, not trial-validated dosing
Local versus systemic injection
Near the injury or elsewhere subcutaneously
Anecdotal reports that route matters little; no study compares them
Clinic-administered protocols
Single 10 mg bladder-wall injection
Also injections into the knee joint and 10 mg then 20 mg intravenous infusions on consecutive days in two adults
Time to effect
Time course
No controlled time course exists
Reported benefits are anecdotal
Imaging check
Day 14
Registered hamstring trial checks imaging at day 14
Return to sport
Within 8 weeks
Registered hamstring trial checks return to sport within 8 weeks

Benefits

Contraindications
  • Pregnant or lactating people
  • Active cancer, cancer treated within the past 5 years, or an unevaluated suspicious lesion (theoretical)
  • Eye disease driven by abnormal blood-vessel growth, such as wet macular degeneration or proliferative diabetic retinopathy (theoretical)
  • Anticoagulant therapy or a known bleeding disorder
  • Age under 18
  • Severe uncontrolled cardiovascular, liver or kidney disease
  • Athletes in tested competition
  • VEGF-blocking drugs (cancer and eye medications; bevacizumab, ranibizumab, aflibercept) (theoretical)
Key Interactions
  • Antiplatelet drugs (blood thinners; clopidogrel)
  • Blood pressure and nitrate drugs (vessel-relaxing medications; amlodipine, lisinopril, nitroglycerin)
  • Cholinesterase inhibitors (dementia drugs; donepezil, rivastigmine, galantamine), low-severity, theoretical
  • Nonsteroidal anti-inflammatory drugs (NSAIDs, common pain relievers; ibuprofen, naproxen, aspirin), severity none known
  • Other repair peptides (TB-500, GHK-Cu, a copper-binding peptide)
  • Growth hormone-axis agents (somatropin, ipamorelin, CJC-1295, MK-677; drugs that trigger growth hormone release)
  • Nitric oxide boosters (L-arginine, L-citrulline, beetroot nitrate)
  • Platelet-rich plasma (concentrated blood platelets) or corticosteroid (anti-inflammatory steroid; triamcinolone, methylprednisolone) injections, severity unknown

Risk & Side Effects

  • Low: Product Contamination & Mislabeling; Injection-Site & Systemic Reactions
  • Speculative: Tumor or Abnormal Vessel Growth; Immune Reactions; Blood Pressure & Nerve-Signaling Effects; Bleeding & Clotting Effects; Unknown Long-Term Safety

Monitoring

Marker Target Why
ALT and AST ≤ 25 U/L each Liver safety
eGFR and creatinine eGFR ≥ 90 mL/min/1.73 m² Kidney clearance
CBC Platelets 150–350 ×10⁹/L Bleeding and clotting baseline
Fasting glucose and HbA1c Glucose 75–90 mg/dL; HbA1c ≤ 5.4% Metabolic safety marker
hs-CRP < 1.0 mg/L Inflammation baseline
TSH 1.0–2.5 mIU/L Thyroid safety marker
Blood pressure < 120/80 mmHg Theoretical blood-vessel widening
Cancer screening status No numeric target; track completion of age-appropriate screening Growth-signaling concern
Dilated eye exam (if retinal vascular disease) No new abnormal vessel growth versus baseline Vessel-growth concern

Cadence: Baseline, about 4 weeks, end of course (about 8 weeks), then every 6–12 months while courses continue; earlier testing for symptoms

Qualitative Assessment

  • Pain level and joint or tendon function (0–10 score versus own baseline)
  • Sleep quality and energy
  • Digestive comfort
  • Dizziness or injection-site reactions